Milton Park Christmas Market

Problems viewing this email? Open in your web browser.
Milton Park Christmas Fair 2015 (55).jpg
Come along to the 2017 Christmas Market
Join us for the annual Christmas Market to grab some last minute Christmas gifts and really get into the Christmas spirit!
This year we will be joined by a variety of stall holders including: Ann Laing flowers, Well Preserved, Moreish Must Haves, Phoenix Trading, Blackberry Cottage and many more.

Come along to enjoy some complimentary  mulled wine, pigs in blankets and minced pies whilst listening to some Christmas Carols and browsing the stalls.

There will be a Christmas jumper competition for those of you with the jazziest and most outrageous jumpers. Christmas champagne will be up for grabs as a prize.

The details:

When: Friday 15th December

Where: Park Centre (white canopy)

Time: 11am – 2pm

For more information, please contact Nancy Leadley on nleadley@mepc.com.
www.miltonpark.co.uk
MEPC Ltd, Innovation Centre, 99 Park Drive, Abingdon, Oxfordshire, OX14 4RY
T: 01235 865555 E: enquiries@miltonpark.co.uk

Acupuncture

From January Tim our Acupuncturist will be coming to the Centre twice a month on the 1st and 3rd Thursday.  If you would like more information on the types of acupuncture he does please let Sue know.

Diagnostic Blood Test May Be Able to Distinguish Between RRMS and PPMS, Researchers Say

Source Mutiple Sclerosis News Today:

In the future, a blood test may make diagnosing multiple sclerosis (MS) much easier, thanks to newly identified biomarker patterns that distinguish between MS patients and healthy people.

The test could also correctly detect primary progressive MS (PPMS) in patients who also had relapsing-remitting disease (RRMS).

Australian researchers suggest that their test — if validated in future prospective studies — could also be used to predict the disease subtype from the outset, or potentially spot the transformation from relapsing to progressive disease earlier than current clinical tests.

This could be particularly important since the emergence of newer-generation treatments — which address axon and brain volume loss — may allow treatment choices that potentially slow disease progression, the research team said.  Read on. 

Cladribine: new oral treatment to be available for people with relapsing MS

Source MS Society:

A new oral treatment for relapsing MS, called cladribine, will be made available on the NHS in England and Wales within the next three months.

Decision makers in Scotland and Northern Ireland are still considering whether to make cladribine available on the NHS.

Cladribine (also known as Mavenclad) is the thirteenth treatment to be approved by the National Institute for Health and Care Excellence (NICE) for relapsing MS. Unlike other oral treatments, which need to be taken every day, cladribine is taken as two courses of tablets, one year apart.  Read on.

Targeting Blood-clotting Protein Can Restore Brain’s Potential to Repair Myelin Layer, Study Shows

Source Multiple Sclerosis News Today:

A blood-clotting protein called fibrinogen prevents myelin production and blocks the neuron remyelination repair process in mice, a study finds.

The study, “Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage,” appeared in the journal Neuron. Its conclusions offer new insights and open new therapeutic avenues for multiple sclerosis (MS) and Alzheimer’s disease, among other illnesses.

One common feature of several neurological disorders is the loss of the myelin layer that normally surrounds neurons. Myelin is essential not only to protect the neurons but also to let them process and transmit the electric pulses they use to communicate with each other. When myelin is degraded, neurons can not work properly and they eventually die.  Read on. 

Do your Christmas Shopping on Amazon?

 

Then please do so by first going to our website (omstc.org) and clicking on the amazon logo at the top of the page.  It really is that easy!

This raises about 5% of the money spent for the Centre and does not cost you a penny! Right now we make ~£10/month from this source, but it could easily be a lot more.

October 100 club winners

October 100 club winners:

1st Prize, £36.25 – Geoff

2nd Prize, £21.75 – Ismay

3rd Prize, £14.50 – Val

Our 100 club only costs £5 a month ask us for details……

Positive results for clinical trial in progressive MS

Source MS Society:

Researchers in the US have proclaimed their initial test of ibudilast for MS a success.

This drug is already used as a medicine for stroke and asthma. It’s now being investigated for its potential to protect nerves in MS and other neurological conditions.

As part of the phase 2 clinical trial, 255 people with primary and secondary progressive MS were given a pill with ibudilast or a placebo. This included some people already on the Disease Modifying Therapies (DMTs) glatiramer acetate and interferon beta.

The study, called SPRINT-MS, found that people taking the drug had a significant reduction in their rate of brain atrophy (shrinkage) compared to those on placebo. This was measured using MRI results.

They also found that the drug was safe and well tolerated by people.  Read on.